Cary, NC, United States
Cary, NC, United States
SEARCH FILTERS
Time filter
Source Type

The use of an oncolytic virus and an aurora kinase inhibitor in the treatment of cancer is disclosed.


The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.


Patent
Biologics | Date: 2017-08-09

A polypeptide comprising a biological activity, said polypeptide comprising a peptide of interest, a single chorionic gonadotropin carboxy terminal peptide attached to the amino terminus of said peptide, two chorionic gonadotropin carboxy terminal peptides attached to the carboxy terminus of said peptide, wherein said polypeptide is the mature polypeptide wherein the signal peptide has been cleaved from the precursor protein, wherein the amino acid sequence of said precursor protein is set forth in SEQ ID NO: 39, and wherein said peptide of interest is hGH.


Patent
Biologics | Date: 2017-07-26

The present disclosure relates to developing cell lines where specific biological pathways are modified, particularly by modifications in the enzymes of the cell. The present disclosure develops protein expression systems wherein specific modification of glycan chain of the protein is achieved, which produces non-fucosylated proteins, including non-fucosylated antibodies. The non-fucosylated proteins are used in developing therapeutic monoclonal antibodies and biomarkers, and in diagnosis and prognosis of various diseases. The present disclosure employs the Transcription Activator like Effector Nuclease (TALEN) technology for inactivating fucosylation in a cell.


Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located on top of and within the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high levels of laminin-5, a cell adhesion bio-active factor shown to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.


Patent
Biologics | Date: 2017-08-02

Mineral-based composition and methods of use thereof in preventing skin damages, such as in subjects exposed to radiation, are provided.


Patent
Biologics | Date: 2017-02-15

A polypeptide consisting of a coagulation factor and one to five human chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation factor, wherein said coagulation factor is Factor VII or Factor VIIa, and wherein the sequence of said CTPs comprises the first 10 amino acids of SEQ ID NO: 4 (i.e., the amino acid sequence SSSSKAPPPS), and optionally, a signal peptide attached to the amino terminus of said coagulation factor. Pharmaceutical compositions comprising the polypeptides and medical uses thereof are also disclosed.


Patent
Dartmouth College and Biologics | Date: 2017-03-22

Compositions comprising deimmunized lysostaphin and methods of using the same, e.g., to treat microbial infection in or on a subject, are provided.


The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (IIp) and compositions thereof from blood.


The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.

Loading Biologics collaborators
Loading Biologics collaborators